Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Oculis Holding AGNASDAQ: OCS

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns positive

Q1 FY2026 Accumulated OCI was CHF 30.1M, compared with -CHF 1.96M a year earlier. Over 3 fiscal years it compounded at +134.1% a year.

Context

  • Accumulated OCI amounted to 12.4% of total assets at the end of Q1 FY2026, up 11.4 pp from a year earlier.
  • Accumulated OCI increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +1639.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 30.1M+6.4% QoQ
Last fiscal yearDec 2025
CHF 28.31M+1230.4% YoY
Year agoMar 2025
-CHF 1.96M+1639.0% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1639.0%——
1 year+1230.4%——
3-year CAGR+134.1%——
5-year CAGR——
10-year CAGR——

Accumulated OCI history

CHF · from the balance sheet

Latest · FY2025
28.31M CHF
Year-over-year change
+1230.4%
4-year CAGR
+156.3%

Accumulated OCI vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +1639.0% is the highest of 3, against a peer median of -30.9%.
  • Accumulated OCI amounts to 12.4% of total assets for OCS, versus a peer median of 0.0%.
OCS Competitors
Accumulated OCI for OCS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OCSOculis Holding AGMar 2026CHF 30.1M CHF+1639.0%+134.1%12.4%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$802K USD-13.1%+6.9%0.3%
OCULOcular Therapeutix, Inc.Mar 2026$0 USD——0.0%
HROWHarrow Health, Inc.Mar 2026$0 USD——0.0%
OTLKOutlook Therapeutics, Inc.Mar 2026$0 USD——0.0%
OKYOOKYO Pharma LimitedSep 2025-$9.03M USD-48.7%—194.5%
Peer median (excluding OCS) —-30.9%+6.9%0.0%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents46.28M19.79M38.33M27.71M81.42M
Short-term Investments0053.32M70.96M131.83M
Net Receivables007.95M777K994.13K
Inventory00000
Other Current Assets911K1.08M004.89M
Total Current Assets47.98M23.66M101.02M104.9M219.14M
Property, Plant & Equipment (Net)1.29M1.12M1.04M1.69M3M
Goodwill00000
Intangible Assets8.72M12.21M12.21M13.29M13.31M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets52K74K89K476K785.89K
Total Non-current Assets10.06M13.4M13.34M15.46M17.09M
Total Assets58.04M37.06M114.35M120.35M236.23M
Account Payables824K3.87M7.6M5.87M1.8M
Short-term Debt0000502.57K
Tax Payables00000
Deferred Revenue005.95M00
Other Current Liabilities01(497K)19.85M34.48M
Total Current Liabilities4.06M12.02M19.09M44.24M36.79M
Long-term Debt113.5M122.45M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities857K91K1.11M1.87M1.34M
Total Non-current Liabilities114.94M123.03M1.54M2.74M3.15M
Total Liabilities119M135.05M20.63M46.97M39.94M
Common Stock335K39K366K446K587.67K
Retained Earnings(72.28M)(110.98M)(199.78M)(285.56M)(384.95M)
Accumulated OCI656K2.21M(1.4M)(2.5M)28.31M
Other Stockholders Equity116.38M16.06M0
Minority Interest00000
Total Equity(60.96M)(97.99M)93.73M73.38M196.29M
Total Debt114.27M123.08M605K1.18M2.32M
Net Debt68M103.3M(37.72M)(26.53M)(79.11M)

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.